A review of available medical therapies to treat moderate-to-severe inflammatory bowel disease
Barreiro E, de la Puente B, Busquets S, Lpez-Soriano FJ, Gea J, Argils JM
Zepbound is a combined glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management in adults who are obese or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, high cholesterol, or cardiovascular disease and is to be used in addition to a reduced calorie diet and increased physical activity
Excessive incretin hormones may also contribute to pancreatic islet cell hyperplasia, leading to hyperinsulinism
Methods: A total of 855 patients who attended the First Affiliated Hospital of Shandong First Medical University from January 2020 to May 2023 were selected as the study participants, who were divided into the training set (598 cases) and the validation set (297 cases) using a simple random sampling method at a ratio of 7:3
